Prevalência de anemia em pacientes em tratamento hemodialítico e sua relação ao uso de eritropoetina e perfil clínicodemográfico

• Autor(a) principal: Ribeiro, Jéssica Cristina
• Data de Publicação: 2017
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFU
• Texto Completo: https://repositorio.ufu.br/handle/123456789/21752
• topic: Anemia; Tratamento Hemodialítico; Insuficiência renal crônica; Chronic renal insufficiency; Eritropoetina; Erythropoietin; Hemodialysis; CNPQ::CIENCIAS DA SAUDE::ENFERMAGEM

Introduction: Chronic renal disease is a serious public health problem and its incidence has been elevated in recent years. It presents progressive character and is associated with high morbidity and mortality rates. Chronic renal disease can bring countless complications to health; Cardiovascular diseases and anemia are the most prevalent and severe, because they are related to a worse evolution of the disease when associated with the chronic renal disease, which could lead to death. Starting from the perspective that chronic renal disease is recognized as a relevant public health problem, taking into consideration that 90% of the clients in dialysis present anemia as a consequence to the chronic renal disease, and make the use of the erythropoietin recombinant human exogenous, which is a medicine high cost for public services, the study of hemoglobin level variability and the response to the treatment of these patients becomes of the utmost importance for managing health services. Objective: To evaluate the effectiveness of erythropoietin exogenous in maintaining adequate levels of hemoglobin and consequent reduction of anemia levels. Methods: Retrospective research, cross-cutting, documentary analysis and quantitative approach were evaluated, in 49 medical charts. Results: The prevalence of anemia was observed in 18 (52.94%) clients in examination conducted six months prior to collecting data, and 16 (47.06%) in the month of collecting data, considering the values advocated for chronic renal patient. Conclusion: erythropoietin may not have a short time response as evaluated here. However, the treatment of anemia with erythropoietin recombinant human exogenous is being efficient and necessary to achieve the recommended indices for the renal patient.